BioMarin obtains recommendation after judicial review
Client(s) BioMarin Pharmaceutical Inc.
Jones Day represented BioMarin Pharmaceutical Inc. in a judicial review application (as an interested party largely aligned with the claimants) in proceedings against The National Institute for Health and Care Excellence ("NICE"). This concerned NICE's decision to not recommend the drug Brineura for the treatment of Batten’s disease. This is an ultra-rare, fatal, genetic brain condition affecting an exceptionally small child population which, untreated, leads to death by the age of 12. The proceedings were settled with NICE exceptionally agreeing to reconsider its decision and recommending Brineura to be funded on the National Health Service. Cerliponase alfa is the first and only treatment for Battens proven to stabilise and slow the progression of the disease.
CO 1998/2019 and CO/2114/2019